Saleh Mansoor 2016 webRank: 
Professor of Medicine
Director, Phase I Program of the Comprehensive Cancer Center
Director, Phase I Clinical Program within the Clinical Center for Translational Science
Medical Director, UAB Clinical Trials Office

Division: 
Hematology & Oncology

Campus Address:
WTI 260J

Mailing Address: 
1720 2nd Avenue South, WTI 260
Birmingham, AL 35294-3300

Phone:
(205) 934-2248 or (205) 996-HOPE (4673)

Email:
mns@uab.edu


For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.

Departmental Affiliation(s):
Primary: Medicine

Medical School:  University of Heidelberg, Heidelberg, West Germany

Internal Medicine Residency:  Henry Ford Hospital, Detroit, Michigan

Fellowship:  Clinical/Research Fellow, Division of Hematology/Oncology, University of Alabama at Birmingham

Certifications:  American Board of Internal Medicince, Certified in Hematology and Medical Oncology

Clinical Interests: Clinical Trials

Personal Statement
My hematology/oncology fellowship training included laboratory investigation in the immune mediated platelet destruction (ITP), as well as, the generation of human monoclonal auto-antibodies from splenic B-cells derived from ITP patients. My NIH funded RO1 grant contributed to my clinical/research interest in the biology and treatment of ITP. I was one of the lead USA investigators on the pivotal trial leading to the FDA approval of the recombinant TPO receptor agonist elthrombopag for the treatment of ITP.

My translational research training included studying monoclonal antibodies against cancer associated target antigens, and I have been the PI or co-PI of a number of breakthrough, first-in-human, clinical trials of mouse, chimeric and humanized anti-tumor monoclonal antibodies conducted at UAB. My laboratory conducted the initial study demonstrating the synergistic role of anti-EGFR MoAb and radiation therapy, and these observations led to the pivotal RTOG trial and FDA approval of Erbitux/RT for the treatment of locally advanced Head/Neck cancer.
                             
As part of my translational research laboratory investigations, I developed and subsequently patented the first mirror-image anti-Id vaccine that mimics the tumor associated GD2 ganglioside.

Over the past 25 years I have been involved in the development, conduct and oversight of clinical trials involving monoclonal antibodies, cytotoxic chemotherapies vaccines, inhibitory small molecules and novel check-point inhibitors and immuno-oncology therapeutics.

During this time I have served as Chairman of UAB Cancer Center’s Protocol Review Committee, a member of the Gene Therapy Panel, and senior scientist and translational clinician at the Cancer Center.

Following my academic career, I spent 15 years in community oncology practice and established a Department of Defense (DOD)-funded Clinical Trials Program, including a first-in-human phase I program, in a community setting.

I recently returned to UAB to head the Phase I, first-in-human drug development program and serve as the Medical Director of the UAB Clinical Trials Office. I am the co-lead investigator (together with Dr. I. Chaudry) of a DOD contract for the conduct of a Phase 1 first-in-human study of EE3SO4, a synthetic estrogen that in animal model has demonstrated unique properties of combating hemorrhagic shock, an application that could revolutionize how we treat various forms of acute hemorrage in patients.

In addition to my interest in clinical and translational research, I have been an ardent promoter of cancer awareness in the LMIC and training clinicians in the early detection and treatment of common cancers.

  1. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
  2. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. J Immunol. 1993 Sep 15;151(6):3390-8.
  3. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
  4. Buribekova R, Shukurbekova I, Ilnazarova S, Jamshevov N, Sadonshoeva G, Sayani S, Saleh, M: Promoting Clinical Breast Evaluations in a Lower Middle Income Country Setting - An Approach Towards Achieving a Sustainable Breast Health Program. J Glob Oncol 4: 1-8, 2018

 Positions and Honors

1985-1986          Instructor in Medicine, Department of Internal Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham and Veterans Administration Hospital, Birmingham, AL
1985-1992          Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham
1988-1992          Assistant Professor of Medicine, Division of Hematology/ Oncology, University of Alabama at Birmingham
1989-1999          Director, Immune Cytopenia Laboratory, University of Alabama at Birmingham
1992-1998          Associate Professor of Medicine, Division of Hematology/ Oncology; Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham
1993-1998          Associate Professor of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham
1995-1999          Associate Director for Clinical Research, Comprehensive Cancer Center, University of Alabama at Birmingham
1995-1999          Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham
1977-Present     Scientist, Center for AIDS Research, University of Alabama at Birmingham
1997-1999          Director for Clinical Research, Division of Hematology/Oncology, University of Alabama at Birmingham
1998-Present     Professor of Medicine, Division of Hematology/Oncology, Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham Professor of Pathology, Department of Pathology, University of Alabama at Birmingham
1999-Present     Associate Director for Clinical Trials Network, University of Alabama at Birmingham, Comprehensive Cancer Center
1999-2015          Staff Member – Georgia Cancer Specialists, Atlanta, GA
1999-2015          Director for Research Development, Georgia Cancer Specialists, Atlanta, GA
2004-Present     Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham
2013-2015          Director for Clinical Research – UAB Cancer Community Network
2014-Present     Member – Research Advisory Committee, Northside Hospital Cancer Institute
2015-Present     Professor of Medicine, Division of Hematology/Oncology Senior Scientist, UAB Comprehensive Cancer Center, Medical Director, UAB Clinical Trials Office, Director, UAB Phase I Program, Medical Director, UAB Clinical Trials Office
2015-Present  Medical Director for the UAB Clinical Trials Office
2018-Present  Professor, Academic Support Department, University of Alabama at Birmingham, School of Nursing   

Visiting Professorship
1988                            Visiting Professor, Aga Khan University Hospital and Medical Center, Karachi, Pakistan
2011                            Visiting lecturer, Aga Khan University Nairobi, Kenya2012-Present  Visiting Professor, Aga Khan University Nairobi, Kenya

Honors

1977                            Gifted Scholar Scholarship Award, Friedricht Ebert Foundation, West Germany
1980                            University of Heidelberg Medical Doctorate - Magna Cum Laude
1986-1989                   Leukemia Society of America Fellowship Award
1986-1989                   Merit Award - Veteran’s Administration Hospital
1995                            Aga Khan Health Board Award for Excellence in Academic Medicine

Contributions to Science


  1. My early work addressed the role of antibody dependent cellular cytotoxicity in immune platelet destruction (ITP). I contributed to the description of the role of platelet associated IgG in immune mediated platelet destruction and 2 decades later, as one of the lead clinical investigators, conducted clinical trials that led to the FDA approval of TPO-receptor agonist elthrombopag in the treatment if ITP.
    1. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. Saleh MN, Moore DL, Lee JY, LoBuglio AF.Blood. 1989 Sep;74(4):1328-31.
    2. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
    3. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. N Engl J Med. 2007 Nov 29;357(22):2237-47.
  1. My laboratory was one of the first that described the synergistic effect of radiation therapy and anti-EGFR MoAb in the treatment of EGFR-expressing tumor cells in vitro. This laboratory finding led to the first in human clinical trial of the MoAb anti-EGFR (Cetuximab) plus radiation therapy for the treatment of locally advanced squamous carcinoma of the head/neck. The positive results from this phase I clinical trial ultimately led to a pivotal randomized trial through the RTOG leading to the FDA approval of Cetuximab combined with radiation therapy in the treatment of locally advanced or recurrent squam. cell carcinoma of the head/neck
    1. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
    2. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW
  1. In 2002 I moved from UABCCC to establish a DOD-funded clinical trials program at the community level as a partnership between UABCCC and Georgia Cancer Specialists (GCS), one of the 5 largest community oncology practices in the USA. In the 15yr I spent at GCS, I continue to play an active academic role at UABCCC while establishing a robust clinical trials program, including first in human trials, at GCS. During this time I was PI of numerous clinical trials, including pivotal studies that led to the FDA approval of a number of novel molecules for the treatment of cancer.
    1. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. N Engl J Med. 2007 Nov 29;357(22):2237-47.
    2. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
    3. Abiraterone and increased survival in metastatic prostate cancer. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators
  1. My clinical investigator training under the mentorship of Al LoBuglio contributed to my dedication to early phase, first-in-human, clinical trials, resulting in my recruitment back to UABCCC to direct the UAB and Cancer Center’s Early Drug Development Phase 1 Program.
    1. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M. Cancer Biother Radiopharm. 2010 Feb;25(1):13-9. doi: 10.1089/cbr.2009.0673.
    2. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. J Immunol. 1993 Sep 15;151(6):3390-8.
    3. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
    4. EMERGE: A randomized Phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthrone T, Yellin MJ, Davis TA, Vahdat LT. J Clin Oncol. 2015 May; 33(14): 1609-19.

Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

Click to view UAB Health System Provider Profile